cas 1787294-51-2|| where to buy tert-Butyl (2-((4-amino-6-chloropyrimidin-5-yl)oxy)ethyl)(methyl)carbamate

Nom du produit:tert-Butyl (2-((4-amino-6-chloropyrimidin-5-yl)oxy)ethyl)(methyl)carbamate

IUPAC Name:tert-butyl N-{2-[(4-amino-6-chloropyrimidin-5-yl)oxy]ethyl}-N-methylcarbamate

: CAS：1787294-51-2; Formule moléculaire：C12H19ClN4O3; Pureté：95%+

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM337408-1g	in stock	ǪŤƥľ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1787294-51-2 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:1787294-51-2; Formule moléculaire:C12H19ClN4O3; Point de fusion:-; Code SMILES:O=C(OC(C)(C)C)N(CCOC1=C(Cl)N=CN=C1N)C; Densité:

: Numéro de catalogue:CM337408; Poids moléculaire:302.76; Point d'ébullition:; N° Mdl:; Stockage:

: Pyrimidines; Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

: Remibrutinib; Novartis announced new positive data from the Phase III REMIX-1 and REMIX-2 studies investigating remibrutinib - a highly selective, oral Bruton's tyrosine kinase (BTK) inhibitor - in people with chronic spontaneous urticaria (CSU) whose symptoms are inadequately controlled by H1-antihistamines. In the studies, remibrutinib met all primary and secondary endpoints at Week 12. Remibrutinib is a potential 'best-in-class' BTK inhibitor. It can covalently bind to the BTK enzyme of B cells and myeloid cells. While strongly inhibiting BTK activity, it reduces the systemic exposure of the drug and reduces the risk of adverse events and drug interactions.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.